Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis

This study has been completed.
Sponsor:
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00082173
First received: April 30, 2004
Last updated: March 26, 2013
Last verified: March 2013
Results First Received: March 26, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Tuberculosis
Intervention: Drug: Moxifloxacin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects with respiratory symptoms suggestive of TB were recruited from the HUCFF outpatient TB clinic as well as other local TB clinics.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients who did not meet enrollment criteria or who did not want to participate in the study were excluded.

Reporting Groups
  Description
Experimental Arm INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
Control Arm INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks

Participant Flow:   Overall Study
    Experimental Arm     Control Arm  
STARTED     74     72  
COMPLETED     64     61  
NOT COMPLETED     10     11  
Withdrawal by Subject                 3                 5  
Lost to Follow-up                 1                 0  
Adverse Event                 1                 0  
Culture negative or resistant at baselin                 5                 6  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
125 had 8-week data (moxifloxacin n=64, ethambutol n=61)

Reporting Groups
  Description
Experimental Arm (Moxi) No text entered.
Control Arm (EMB) No text entered.
Total Total of all reporting groups

Baseline Measures
    Experimental Arm (Moxi)     Control Arm (EMB)     Total  
Number of Participants  
[units: participants]
  74     72     146  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     72     71     143  
>=65 years     2     1     3  
Age  
[units: years]
Mean ± Standard Deviation
  32.5  ± 11.7     35.7  ± 12.0     34.1  ± 11.9  
Gender  
[units: participants]
     
Female     34     22     56  
Male     40     50     90  
Region of Enrollment  
[units: participants]
     
Brazil     74     72     146  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Patients With Sterile Sputum Cultures   [ Time Frame: 8 weeks ]

2.  Secondary:   Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications   [ Time Frame: 8 weeks ]
  Hide Outcome Measure 2

Measure Type Secondary
Measure Title Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications
Measure Description Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications
Time Frame 8 weeks  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
DAIDS Table of Adverse Events

Reporting Groups
  Description
Experimental Arm INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
Control Arm INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks

Measured Values
    Experimental Arm     Control Arm  
Number of Participants Analyzed  
[units: participants]
  74     72  
Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications  
[units: Participants]
  0     0  

No statistical analysis provided for Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications




  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Dr. Richard Chaisson
Organization: Johns Hopkins University
phone: 410-955-1755
e-mail: rchaiss@jhmi.edu


No publications provided by Johns Hopkins University

Publications automatically indexed to this study:

Responsible Party: Dr. Richard E. Chaisson, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00082173     History of Changes
Other Study ID Numbers: FD-R-002135-01
Study First Received: April 30, 2004
Results First Received: March 26, 2013
Last Updated: March 26, 2013
Health Authority: United States: Food and Drug Administration